Netherlands vs Serbia: Life science patents granted, by technology
Netherlands
101 patents
in 2023
Serbia
277 patents
in 2023
Netherlands rank
15th
Serbia rank
12th
Life science patents granted, by technology over time
- Netherlands
- Serbia
How they compare
Serbia currently reports 277 patents against 101 patents in Netherlands, a difference of 176 patents.
That makes Serbia's figure about 2.7 times Netherlands's.
The two have swapped places 1 time across 16 shared years of data; in 2008 it was Netherlands ahead.
Netherlands ranks 15th and Serbia ranks 12th of 65 countries.
Across the 3 decades both report, Netherlands averaged higher in 1 and Serbia in 2.
Head to head by decade
| Decade | Netherlands | Serbia | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 13.5 patents | 1 patents | 12.5 patents | Netherlands |
| 2010s | 15.8 patents | 243.7 patents | 227.9 patents | Serbia |
| 2020s | 55.25 patents | 358.75 patents | 303.5 patents | Serbia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher life science patents granted, by technology, Netherlands or Serbia?
- Serbia, at 277 patents against 101 patents in Netherlands as of 2023.
- What is the difference in life science patents granted, by technology between Netherlands and Serbia?
- 176 patents, with Serbia ahead.
- How many years of comparable data are there for Netherlands and Serbia?
- 16 years are reported by both, from 2008 to 2023.
- How do Netherlands and Serbia rank globally for life science patents granted, by technology?
- Netherlands ranks 15th and Serbia ranks 12th of 65 countries.
- Where does this data come from?
- World Intellectual Property Organization (WIPO) (2025) β processed by Our World in Data, published as Life science patents granted, by technology. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of pharmaceutical patents granted by the filing office in a given year. Pharmaceutical patents typically cover new drugs, biological treatments or vaccines.